A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study

Kupczyk, Maciej; Majak, Paweł; Kuna, Piotr; Asankowicz-Bargiel, Beata; Baranska, Eliza; Dobek, Rafał; Garbicz, Sławomir; Jerzyńska, Joanna; Latos, Anna; Machowiak, Wojciech; Majorek-Olechowska, Bernadetta; Olech-Cudzik, Anna; Poziomkowska-Gęsicka, Iwona; Rulewicz-Warniello, Miroslawa; Świderska, Anna; Tarnowski, Michal; Kopyto, Przemyslaw

doi:10.1016/j.rmed.2020.106274

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although both can significantly mitigate the symptoms of patients, budesonide powder is too irritating, which may increase the risk of adverse reactions in patients [ 5 ]. In recent years, salmeterol and fluticasone powder has emerged as a mainstay for bronchial asthma, and the drug is composed of fluticasone propionate and salmeterol [ 6 ]. Since the former aims to improve lung function, the latter targets to improve patients' overall health, these two treatments complement one another [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Zhang

Liu

Mao

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of fluticasone and salmeterol dry powder in treating patients with bronchial asthma and its effects on inflammatory factors and pulmonary function. Methods. One hundred patients with bronchial asthma, admitted to our hospital between April 2019 and June 2020, were enrolled and assigned into two groups using the random number table method. The observation group (n = 50) received budesonide powder, and the experimental group received fluticasone and salmeterol dry powder. The two groups were compared with regard to clinical efficacy, inflammatory factors, pulmonary function, and adverse reactions. Results. In the experimental group, the total effective rate of treatment was significantly higher than that in the observation group ( P < 0.05 ); after treatment, the levels of inflammatory factors in the experimental group were lower than those in the observation group ( P < 0.05 ); after treatment, lung function in the experimental group was significantly higher than that in the observation group ( P < 0.05 ); the incidence of adverse reactions in the experimental group was significantly lower than that in the observation group ( P < 0.05 ). Conclusion. Salmeterol and fluticasone powder has shown impressive clinical benefits in the treatment of bronchial asthma patients. It might be a viable approach to reduce inflammatory factors and improve pulmonary function. Moreover, its good clinical safety profile makes it a promising treatment that ought to be promoted and used widely.

show abstract

Section: Introductionmentioning

confidence: 99%